Pooled safety results over 24 weeks from the enhance program with ensifentrine, a novel dual phosphodiesterase (pde) 3 and 4 inhibitor
CHEST（2023）
关键词
novel dual phosphodiesterase,ensifentrine,inhibitor,enhance program
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要